glp-1 receptor agonists cardiovascular benefits The Biology of Glucagon-like Peptide-1 Cardiovascular Effects of Glucagon-Like Peptide-1

A., Abou-Kheir, W., Davicioni, E., Lee, D

Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer

16 This is especially seen in assisted reproductive settings used due to infertility problems stemming from advanced age and poor ovarian reserve, where it can play a role in mitigating metabolic and reproductive disturbances and enhancing the odds of pregnancy post-IVF

Recent scientific studies have found that patients taking semaglutide significantly more likely to develop NAION than non-users a risk that the drug manufacturers did not adequately disclose

From its initial use in the treatment of type 2 diabetes to its expansion to 12 indications such as obesity, cardiovascular disease, chronic kidney disease, and metabolic dysfunction related fatty liver disease (MASLD), the annual sales of GLP-1 drugs exceeded 100 billion dollars, and its research and development funding reached a historical peak of 21.72 million dollars in 2025

doi: 10.1007/s13300-025-01784-x [DOI] [PMC free article] [PubMed] [Google Scholar] 205.Packer M, Zile MR, Kramer CM, et al